ONCOTELIC THERAPEUTCS INC - OTLC STOCK NEWS

Oncotelic Therapeutics (OTLC) recently shared presentation materials from the Society for Neuro-Oncology’s 27th Annual Meeting held from November 16-20, 2022. Notable abstracts included studies on OT-101, an antisense therapy targeting TGF-β2 for glioblastoma and pediatric diffuse intrinsic pontine glioma (DIPG). The company is advancing a Phase 1 study protocol for OT-101 in pediatric DMG, emphasizing the urgent need for new treatments in this area. The participation in the SNO meeting underscored the clinical promise of OT-101 and garnered interest from key opinion leaders in the field.

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced the release of presentation materials from the SITC 37th annual meeting held in Boston, discussing their OT-101 anti-TGF-β immunotherapy. Key stakeholders and opinion leaders were engaged, with plans for upcoming clinical studies emphasizing its efficacy against pancreatic cancer. OT-101 has completed multiple clinical trials, including those for COVID-19 and pediatric brain cancer (DIPG). The company is focused on improving treatment outcomes for rare diseases, including Parkinson's Disease and Erectile Dysfunction.

Oncotelic Therapeutics (OTLC) announced the submission of a Phase 1 clinical study protocol to the FDA for OT-101, a TGF-β2 inhibitor, aimed at treating pediatric patients with diffuse midline glioma (DMG). This open-label trial, G101, will assess the safety and tolerability of administering OT-101 via intraventricular injection. DMG is a highly aggressive brain tumor with a poor prognosis. OT-101 has previously shown activity in relapsed cancer cases and received orphan designation, indicating its potential to address unmet medical needs in pediatric oncology.

Oncotelic Therapeutics, Inc. (OTLC) announced a contract approval with BARDA for the development of OT-101, targeting long-term COVID-19 respiratory distress effects. The project encompasses collecting clinical data from COVID-19 patients in Peru and Argentina to support future trials. OT-101, which has completed seven clinical trials, aims to address various indications including COVID-19 and DIPG. The project is fully funded by federal sources, enhancing the potential for advancing therapeutic options in the post-COVID landscape.

Oncotelic Therapeutics (OTLC) has officially launched an animal health division, emphasizing its commitment to innovative drug development for animals, particularly pets. The initiative aims to utilize blockchain technology and a decentralized autonomous organization (DAO) to improve drug development processes. Chairman and CEO Dr. Vuong Trieu expressed optimism about the integration of DAOs within the animal health sector and the potential for existing drug candidates to succeed in this new market. The company acknowledges the inherent risks in its forward-looking statements related to future product development and regulatory approvals.

Oncotelic Therapeutics (OTCQB:OTLC) announced its presentation at the SITC 37th Annual Meeting, scheduled for November 10-12, 2022, in Boston, MA. The presentation, titled Mechanism of Action for OT-101 TGF-ß immunotherapy, focuses on the ongoing development of OT-101 for pancreatic cancer treatment. CEO Dr. Vuong Trieu highlighted that pancreatic cancer has a low survival rate, urging the need for innovative therapies. The P001 trial showed 54% disease control in evaluable patients, indicating promising results for OT-101 against this aggressive cancer.

Oncotelic Therapeutics (OTCQB:OTLC) has announced two poster presentations at the 2022 Society for Neuro-Oncology Annual Meeting scheduled for November 16-20, 2022, in Tampa Bay, Florida. The presentations will focus on OT-101, a treatment for glioblastoma and DIPG, emphasizing its potential after radiation therapy. Dr. Vuong Trieu, CEO, highlighted the urgent need for innovative treatments for DIPG, a fatal pediatric brain cancer. Oncotelic aims to accelerate OT-101's clinical development following the formation of a joint venture with Sapu Bioscience.

Oncotelic Therapeutics (OTLC) reported a net profit of $17 million for Q2 2022, driven by a fair value of $22.6 million for its joint venture (JV) with Dragon Overseas and GMP Biotechnology. Noteworthy highlights include a significant reduction in expenses by over $3.5 million compared to Q2 2021 and a strategic plan for OT-101's further development, targeting pediatric cancers. The JV is positioned for an IPO, and Oncotelic anticipates lower R&D and G&A expenses moving forward.

Oncotelic Therapeutics (OTCQB:OTLC) announced participation in Biotechgate Digital Partnering from Aug 29 - Sep 2, 2022. The company focuses on developing treatments for rare conditions like Parkinson's disease and certain cancers, particularly pediatric cancers. Oncotelic has joint ventures and its own product candidates, including AL-101 for Parkinson's and erectile dysfunction. As of now, over 1 million patients in the US have Parkinson's, with numbers projected to rise. The company has completed several clinical trials for its therapies, including OT-101 for cancer and COVID-19.